Progenics Pharmaceuticals — Technical Presentation (June 2017)
40 slides from Progenics Pharmaceuticals's technical presentation, Jun 20, 2017
Slide 1: Ultratrace lobenguane I-131 (AZEDRA) in Patients with Malignant or Recurrent Pheochromocytoma/Paraganglioma
Ultratrace® lobenguane I-131 (AZEDRA™) in Patients with Malignant or Recurrent Pheochromocytoma / Paraganglioma Camilo Jimenez, MD Associate Professor Department of Endocrine Neoplasia and Hormonal Disorders The University of Texas MD Anderson Cancer Center
Slide 2: Outline
Outline * Anatomical definitions * Clinical manifestations * Therapeutics: * Malignant pheochromocytomas/paragangliomas * Therapeutic Challenges * Phase 2b Clinical Trial with Azedra for Patients with Recurrent or Malignant Pheochromocytoma/Paraganglioma
Slide 3: Anatomical definitions
Anatomical definitions
Slide 4: Paraganglia
Paraganglia * Group of neuro- endocrine cells that migrate during embryonic development with components of the parasympathetic and sympathetic ganglia.
Slide 5: Pheochromocytomas
Pheochromocytomas * Chromaffin (+) tumors originated in the adrenal medulla. They may produce catecholamines such as epinephrine and/or norepinephrine predisposing to cardiovascular disease and other complications. WHO 2004
Slide 6: Slide 6
Slide 7: Paragangliomas
Paragangliomas * Paragangliomas are tumors that arise from extra- adrenal chromaffin cells and can originate either in the parasympathetic or sympathetic ganglia. * Parasympathetic: chemodectomas, carotid body tumors, glomus jugular tumors, etc. * Sympathetic: thoracic, abdominal, and pelvic tumors.
Slide 8: Slide 8
Slide 9: Clinical Manifestations
Clinical Manifestations * More than 100 symptoms and signs have been described in association with these tumors. Hypertension, headaches, palpitations, and diaphoresis are the most common ones.
Slide 10: Clinical manifestation
Clinical manifestation Symptom Headaches Palpitations Diaphoresis Pallor Nausea Weight loss Flushing Fatigue Anxiety — Panic attacks Sustained hypertension Paroxysmal hypertension Orthostatic hypotension Frequency % 60-90 50-70 55-75 40-45 20-40 10-20 20-40 20-40 25-40 Lenders, Lancet 2005
Slide 11: Gastrointestinal disease
Gastrointestinal disease
Slide 12: Case presentation
Case presentation * 46 year-old man with history of malignant paraganglioma presents with hypertension, palpitations, headaches, sweats, and constipation for longer than 1 year (last bowel movement was hard and happened 8 days ago). The patient noticed fever, nausea, and lack of appetite. On physica
Slide 13: Case presentation
Case presentation
Slide 14: Constipation
Constipation * It happens in 6% of patients * It is usually mild but occasional cases are severe * It may predispose to hemorrhoids, stercoral ulcers, toxic megacolon, bleeding, perforation, and obstruction. * Alpha- and beta-blockers do not treat constipation. Laxatives are required and their chose
Slide 15: Clinical manifestations
Clinical manifestations * The clinical presentation of these tumors is highly variable and can overlap with the signs and symptoms associated with numerous other non- related clinical conditions. * The critical first step in making the diagnosis is to suspect the presence of a tumor.
Slide 16: Genetics
Genetics
Slide 17: Strong hereditary background MEN2, VHL, NF1, SDHx
Strong hereditary background 50 MEN2, VHL, NF1, SDHx, TMEM127, MAX, FH EPAS-1 @ % hereditary cases 1990 2005 2020 Neumann, NEJM, 2001; Amar L. JCO, 2005; Jimenez, JCEM, 2006; Dahia, 2011
Slide 18: Malignant Pheochromocytoma and Paraganglioma
Malignant Pheochromocytoma and Paraganglioma
Slide 19: Malignant PH or SGP
Malignant PH or SGP * No molecular or histologic markers exist for determining whether a PH or SPG is malignant * Malignancy is defined only by the presence of metastases * The most common locations of metastatic spread are the lymph ganglia, bones, liver, and lungs * Liver, pancreas, and kidneys ma
Slide 20: Malignant pheochromocytoma
Malignant pheochromocytoma
Slide 21: Road to Diagnosis
Road to Diagnosis * Signs/symptoms may be present but the association with a pheochromocytoma/paraganglioma is not made * Patients may present with big tumors and/or distant spread
Slide 22: Treatment Challenges for Malignant Pheo/Para Patients
Treatment Challenges for Malignant Pheo/Para Patients * High morbidity and mortality rates from: * Excessive catecholamine secretion ¢ Hypertension Cardiovascular complications Gastrointestinal disease Bulky disease for which no curative treatment is available * Low overall survival (OS) rates; only
Slide 23: Current Management of Malignant Pheo/Para
Current Management of Malignant Pheo/Para * No approved treatments * Most patients treated with chemotherapy or MIBG therapy * Responses limited * Duration of response limited Surgery Many tumors unresectable Localized radiotherapy Disease is frequently extensive Chemotherapy Toxicity; limited effic
Slide 24: Overall survival comparing surgical resection versus no surgery
Overall survival comparing surgical resection of the primary tumor versus no surgery Alejandro Roman, Annals of Surgery, 2017
Slide 25: Malignant pheochromocytoma
Malignant pheochromocytoma
Slide 26: Meta-Iodobenzylguanidine (MIBG)
Meta-lodobenzylguanidine (MIBG) * Described by Wieland et al in 1979 at the University of Michigan * lodination in the meta position * Stable and highly resistant to in vivo metabolism + ~90% excreted intact in the urine * 40-50% within 24 hours * MIBG is not a norepinephrine analog * Substrate for
Slide 27: Norepinephrine Transporter
Norepinephrine Transporter
Slide 28: Rationale for the use of MIBG in patients with pheo/para
Rationale for the use of MIBG in patients with pheo/para * NET is highly expressed in tumors of neural crest origin such as pheo/para and neuroblastoma * Radio iodinated MIBG has been used for both diagnostic and therapeutic applications for neuroendocrine tumors * Conventional (carrier added) |-131
Slide 29: Ultratrace vs. Conventional I-131 MIBG
Ultratrace® vs. Conventional I|-131 MIBG Similarity: = Both MIBG labeled at the meta position with I-131 Differences: Manufacturing From solid aoe precursor | By simple isotope exchange process (resin) Specific activity of High drug product Unlabeled MIBG Large amount each dose Safety No cold MIBG,
Slide 30: Only 1 in 1,000 molecules of MIBG contains I-131
Only 3 in 1,000 molecules of MIBG contains [1341]
Slide 31: Every Azedra molecule contains I-131
Every Azedra molecule contains [4341]
Slide 32: Phase 2b trial of Azedra in Malignant or Recurrent Pheochromocytoma and Paraganglioma
Phase 2b trial of Azedra in Malignant or Recurrent Pheochromocytoma and Paraganglioma
Slide 33: Phase 2b Trial: Key eligibility and study endpoints
Phase 2b Trial: Key eligibility and * Primary Endpoints: * Reduction of antihypertensive medications by 2 50% for at least 6 months * Secondary Endpoints: + Safety * Tumor Response by RECIST and tumor markers * Overall Survival study endpoints ° Key Eligibility: * Documented pheo/para Ineligible for
Slide 34: Trial Design
Trial Design * Multi-center, open label * Patients receive dosimetry dose to determine tumor avidity to Azedra * Patients receive 2 therapy doses, 3 months apart * Enrolled 68 patients
Slide 35: Trial achieved primary endpoint
Trial achieved primary endpoint * Met the primary endpoint evaluating the proportion of patients who achieved a 250% reduction of all antihypertensive medication for at least six months. * Under the study protocol, the primary endpoint is achieved if the lower limit of the two-sided 95% confidence i
Slide 36: Favorable Tumor Responses
Favorable Tumor Responses * Key secondary endpoint: the proportion of patients with overall tumor response as measured by RECIST * 92.2% of evaluable patients (59/64) who received at least one AZEDRA therapeutic dose achieved partial response or stable disease Overall Tumor Response Assessment per R
Slide 37: Safety Overview
Safety Overview * Generally well tolerated * Most common TEAEs were consistent with prior studies: * Nausea Thrombocytopenia Anemia Fatigue Leukopenia Neutropenia, consistent with prior studies
Slide 38: Conclusions
Conclusions * The trial met the primary endpoint evaluating the proportion of patients who achieved a 250% reduction of all antihypertensive medication for at least six months * 92.2% of evaluable patients (59/64) who received at least one AZEDRA therapeutic dose achieved partial response or stable
Slide 39: Conclusions
Conclusions ¢ Azedra was generally well tolerated * AEs consistent with prior studies * Azedra may be a useful treatment for patients with iobenguane-avid metastatic and/or recurrent pheochromocytoma/paraganglioma, an orphan disease with no FDA approved therapies
Slide 40: [email protected]
Progenics Pharmaceuticals — Technical Presentation (June 2017) on 6ix